ATXI: Avenue Therapeutics, Inc. Total Debt to Capital

This chart helps assess the debt load of Avenue Therapeutics (ATXI), whose future revenues rely on the implementation of hospital-grade tramadol and the fight against neurodegeneration. The accompanying daily price chart shows the metric at 0.00, which is critical given strict opioid controls and litigation threats. FDA approval delays are creating a financial deficit, forcing the company to raise new capital due to risky clinical trials.

This indicator measures the degree of financial leverage by comparing total liabilities to net asset value to determine the business's dependence on borrowed capital. The current value of 0.00 in the debt-to-equity ratio history reflects the ability of Avenue Therapeutics (ATXI) to fund the development of CNS drugs without a critical debt load, which determines the company's overall stability.